Literature DB >> 1647959

T cell receptor/CD3 and CD28 use distinct intracellular signaling pathways.

R A Van Lier1, M Brouwer, E D De Groot, I Kramer, L A Aarden, A J Verhoeven.   

Abstract

Ligation of the T cell membrane antigen CD28 strongly enhances cytokine secretion in human T lymphocytes that are activated via T cell receptor (TcR)/CD3 or CD2 molecules. This study was undertaken to investigate whether, as has been indicated for activation via TcR/CD3, stimulation via CD28 is dependent on the activation of protein kinase C (PKC). Two inhibitors of PKC, 1-alkyl 2-methyl-glycerol and staurosporine, caused a dose-dependent inhibition of T cell proliferation induced by anti-CD3 monoclonal antibodies (mAb). The induction of interleukin (IL) 2 secretion was found to be more sensitive to the effects of the PKC inhibitors than the up-regulation of IL 2 receptor expression. In marked contrast, the anti-CD28 mAb-mediated enhancement of T cell proliferation and IL 2 secretion were insensitive to the action of either compound. We conclude that two independent signaling pathways may be operational in human T cells. The first used by TcR/CD3 depends on the activation of PKC, whereas the second is employed by CD28 and functions independently of PKC.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1647959     DOI: 10.1002/eji.1830210731

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Regulation of T-cell differentiation by CD2 and CD28 accessory molecules.

Authors:  R de Jong; P Stokkers; E Lamme; J M Kool; F Borst; M Brouwer; F Miedema; R A van Lier
Journal:  Immunology       Date:  1991-10       Impact factor: 7.397

2.  Co-stimulation with anti-CD28 (Kolt-2) enhances DNA synthesis by defective T cells in common variable immunodeficiency.

Authors:  M E North; A N Akbar; N Borthwick; K Sagawa; M Funauchi; A D Webster; J Farrant
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

Review 3.  CD28/CTLA-4 and CD80/CD86 families: signaling and function.

Authors:  J M Slavik; J E Hutchcroft; B E Bierer
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

Review 4.  CD28: a signalling perspective.

Authors:  S G Ward
Journal:  Biochem J       Date:  1996-09-01       Impact factor: 3.857

5.  Efficient expansion of tumor-infiltrating lymphocytes from solid tumors by stimulation with combined CD3 and CD28 monoclonal antibodies.

Authors:  M J Flens; W M Mulder; H Bril; M B von Blomberg van de Flier; R J Scheper; R A van Lier
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

6.  Inhibition of anti-CD3 monoclonal antibody-induced T-cell proliferation by dexamethasone, isoproterenol, or prostaglandin E2 either alone or in combination.

Authors:  L Elliott; W Brooks; T Roszman
Journal:  Cell Mol Neurobiol       Date:  1992-10       Impact factor: 5.046

7.  Signalling through CD28 T-cell activation pathway involves an inositol phospholipid-specific phospholipase C activity.

Authors:  J Nunes; S Klasen; M D Franco; C Lipcey; C Mawas; M Bagnasco; D Olive
Journal:  Biochem J       Date:  1993-08-01       Impact factor: 3.857

8.  IL-2 gene expression and NF-kappa B activation through CD28 requires reactive oxygen production by 5-lipoxygenase.

Authors:  M Los; H Schenk; K Hexel; P A Baeuerle; W Dröge; K Schulze-Osthoff
Journal:  EMBO J       Date:  1995-08-01       Impact factor: 11.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.